Exarafenib

For research use only. Not for therapeutic Use.

  • CAT Number: I043409
  • CAS Number: 2639957-39-2
  • Molecular Formula: C26H34F3N5O3
  • Molecular Weight: 521.58
  • Purity: ≥95%
Inquiry Now

Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity[1][2].
Exarafenib (RAF/KIN_2787; 1-10000 nM; 24 h) inhibits RAF-dependent melanoma cell line growth. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines[1].
Exarafenib (RAF/KIN_2787; 3-30 mg/kg; Orally; twice daily; 29 days) is effective against BRAFmut & NRASmut human melanoma xenografts in vivo[1].


Catalog Number I043409
CAS Number 2639957-39-2
Synonyms

(3S)-N-[3-[2-[[(2R)-1-hydroxypropan-2-yl]amino]-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

Molecular Formula C26H34F3N5O3
Purity ≥95%
InChI InChI=1S/C26H34F3N5O3/c1-17-3-4-21(31-25(36)34-6-5-19(15-34)14-26(27,28)29)13-22(17)20-11-23(30-18(2)16-35)32-24(12-20)33-7-9-37-10-8-33/h3-4,11-13,18-19,35H,5-10,14-16H2,1-2H3,(H,30,32)(H,31,36)/t18-,19+/m1/s1
InChIKey GZMYLSJUNSCMTD-MOPGFXCFSA-N
SMILES CC1=C(C=C(C=C1)NC(=O)N2CCC(C2)CC(F)(F)F)C3=CC(=NC(=C3)N4CCOCC4)NC(C)CO
Reference

[1]. Miller N, et, al. Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in combination with MEK inhibition in preclinical models of human NRAS mutant melanoma.2022 Jun 2;40(16): e15099.

[2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical

Request a Quote